This clinical research program will explore the role of BACE (beta-site amyloid precursor protein cleaving enzyme) inhibition in Alzheimer’s disease.
Inhibition of BACE reduces amyloid beta production, which is thought to lead to a reduction in amyloid plaque formations caused by the aggregation of toxic amyloid oligomers and protofibrils in the brain. It’s believed that decreasing the formation of these plaques may potentially slow Alzheimer’s disease progression.5
Consists of two global Phase III clinical studies with identical protocols:
MISSION AD1 - Study 301
MISSION AD2 - Study 302
Multicenter, placebo-controlled, double-blind, parallel-group Phase III clinical studies of 1,330 patients with positive biomarkers for brain amyloid pathology.
To assess the efficacy and safety of BACE inhibition in early Alzheimer’s disease (including mild cognitive impairment due to Alzheimer’s and a subset of very mild Alzheimer’s disease dementia).
I agree with the Terms of Information Use below
Eisai is at the forefront of researching new strategies for the earlier diagnosis and treatment of Alzheimer’s disease and other forms of dementia.
We have a strong legacy in neurology as a human health care company and global pharmaceutical organization. Committed to discovering and developing innovative therapies for unmet patient needs, we established the Neurology Business Group in 2016, comprising all functions relating to drug discovery research and clinical research.
1. World Health Organization. Dementia Fact Sheet. May 2017. http://who.int/mediacentre/factsheets/fs362/en/. Accessed June 22, 2017.
2. Alzheimer’s Association. May 2014. http://alz.org/global/. Accessed June 22, 2017.
3. U.S. National Institutes of Health. A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease (MissionAD1). https://clinicaltrials.gov/ct2/show/NCT02956486. Accessed June 22, 2017.
4. U.S. National Institutes of Health. A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease (MissionAD2). https://clinicaltrials.gov/ct2/show/NCT03036280. Accessed June 22, 2017.
5. Vassar, R. BACE1 Inhibitor Drugs in Clinical Trials for Alzheimer’s Disease. Alzheimer's Research & Therapy:2014;6.89:1-14.
6. Alzheimer's Association. Mild Cognitive Impairment (MCI): Signs, Symptoms, & Diagnosis. May 2017. http://www.alz.org/dementia/mild-cognitive-impairment-mci.asp. Accessed June 22, 2017.
7. Alzheimer's Association. What Is Alzheimer's? May 2017. http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp. Accessed June 22, 2017.
8. Alzheimer's Association. Stages of Alzheimer's & Symptoms. June 2017. http://www.alz.org/alzheimers_disease_stages_of_alzheimers.asp#mild. Accessed June 22, 2017.
9. Alzheimer's Association. Why Get Checked. June 2017. http://www.alz.org/alzheimers_disease_why_get_checked.asp. Accessed June 22, 2017.
10. Alzheimer's Association. Alzheimer’s and Dementia Testing for Earlier Diagnosis. June 2017. http://alz.org/research/science/earlier_alzheimers_diagnosis.asp. Accessed June 22, 2017.
11. National Institutes of Health. What Are Clinical Trials? May 2017. https://www.nhlbi.nih.gov/studies/clinicaltrials. Accessed June 22, 2017.